A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
This is a single center, double-blind, randomised parallel group design study to investigate
the effects of AER 001 on the late phase asthmatic resonse in asthmatic subjects. AER 001 is
to be administered subcutaneously (25 mg, once daily) for 28 days. The asthmatic subjects
will be challenged with allergen both before and after AER 001 treatment (at screen and at
Day 28). The primary outcome will be late phase sthmatic response (the max drop in FEV1 from
4-10 hours after an allergen challenge).